This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
$1 buys you full access to ALL of TheStreet's Subscription Services! Learn More

Protein Design's Drug Gets Mixed Marks

Protein Design Labs (PDLI) said Friday that a late-stage test of its experimental cancer drug Zamyl produced mixed results.

Zamyl is being developed to treat acute myeloid leukemia. In a late-stage test of 191 patients, 43% of patients taking Zamyl plus traditional chemotherapy drugs successfully reduced the number of cancer cells in their blood. This is compared with just 26% of patients taking chemotherapy drugs alone.

PDL called these results a success, but on an equally important measure, Zamyl failed. The company said patients didn't reach this "complete response" target within 70 days of starting treatment. This time target was the primary goal of the late-stage test.

In recent trading on Friday, the company's stock was lower by $1.71, or 4.2%, to $38.86.

PDL is best known as a drug technology company that licenses its know-how to other biotech firms. But with products such as Zamyl, the company is trying to use its technology to develop its own drugs .

The mixed Zamyl results do not come as much of a surprise. Wall Street analysts had been downplaying expectations for the drug in recent weeks. The company uwrapped the drug's results at the annual meeting of the American Society of Hematology, which starts today and runs through Dec. 11. On Monday, PDL will release partial results from testing on another of its young drugs, Remitogen, for the treatment of non-Hodgkin's lymphoma.

PDL is testing Zamyl on patients who failed other treatments for acute myeloid leukemia, or who had relapsed within one year. In the trial, a complete response was defined as a patient with less than 5% of cancerous cells in his body and who no longer required blood transfusions.

The 43% overall response rate for patients taking Zamyl and chemotherapy was measured using a set of criteria also used to test a competing and approved leukemia drug, Mylotarg, which is sold by American Home Products (AHP).

But under a more stringent definition of "complete response," Zamyl didn't perform as well: It produced a complete response in 30% of patients, compared with 21% of patients using chemo drugs alone, the company said.

PDL executives believe the trial, despite its mixed results, proves that Zamyl can be an effective and safe leukemia drug.

"We are delighted by the positive results we have seen in this trial, and the potential benefits Zamyl might provide to myeloid leukemia patients," said company CEO Larry Korn, in a statement. "If the complete analysis of the data, which PDL will be conducting over the next two or three months, confirms this preliminary review, PDL plans to hold discussions with the FDA and European regulatory authorities. We would then plan to file for marketing clearance for Zamyl in the United States and Europe."

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,814.94 -2.96 -0.02%
S&P 500 2,067.84 -1.57 -0.08%
NASDAQ 4,758.1550 +3.2630 0.07%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs